{"id":"sivextro-200-milligrams-oral-tablet","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nausea"},{"rate":"3-7","effect":"Headache"},{"rate":"3-5","effect":"Diarrhea"},{"rate":"2-5","effect":"Vomiting"},{"rate":"1-3","effect":"Peripheral neuropathy"},{"rate":"1-2","effect":"Optic neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tedizolid is an oxazolidinone antibiotic that binds to the bacterial 70S ribosome and inhibits peptidyl transferase, preventing peptide bond formation and halting protein synthesis. This bacteriostatic mechanism is effective against a broad spectrum of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).","oneSentence":"Sivextro (tedizolid) inhibits bacterial protein synthesis by binding to the bacterial ribosome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:22.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"},{"name":"Community-acquired bacterial pneumonia (CABP)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sivextro 200 milligrams Oral Tablet","genericName":"Sivextro 200 milligrams Oral Tablet","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sivextro (tedizolid) inhibits bacterial protein synthesis by binding to the bacterial ribosome. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}